Jafron Biomedical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
April 25, 2024 at 05:24 pm IST
Share
Jafron Biomedical Co.,Ltd. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was CNY 744.34 million compared to CNY 572.56 million a year ago. Revenue was CNY 744.34 million compared to CNY 572.56 million a year ago.
Net income was CNY 284.77 million compared to CNY 196.53 million a year ago. Basic earnings per share from continuing operations was CNY 0.3512 compared to CNY 0.246 a year ago. Diluted earnings per share from continuing operations was CNY 0.3495 compared to CNY 0.2427 a year ago.
Jafron Biomedical Co.,Ltd. is a China-based company principally engaged in the research, design, manufacture and distribute of biological materials and medical equipment. The Companyâs products include disposable hemoperfusion devices, hemoperfusion machine, disposable bilirubin adsorbers, DX-10 blood purification machine, suture needle, as well as resins bandage, among others. The Companyâs products are applied in uremia, poisoning, severe liver diseases, autoimmune diseases, as well as multisystem organ failure, among others. The Companyâs products are applied in 31 provinces, more than 3000 hospitals in China.
JAFRON BIOMEDICAL CO.,LTD. 
